Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

Netherlands: Researchers have discovered in a new study that higher baseline blood eosinophil counts were associated with an ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is and among those treated with GLP-1 RAs vs DPP-4is. HealthDay News — For ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in understanding and managing COPD, particularly in relation to its ...

Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab vs placebo. Mepolizumab was found to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Witt: I'm so glad ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...